- Silexion Therapeutics Corp published an updated corporate presentation on **September 2, 2025**, which will be presented at the H.C. Wainwright Global Investment Conference from **September 8-10, 2025**.  **[2022416_0001178913-25-003205_zk2533739.htm:1]** 
- The company completed a **Phase 2 proof-of-concept clinical trial** for its first-generation product, **siG12DLoder siRNA**, in locally advanced pancreatic cancer, demonstrating a **9.3 months improvement in overall survival**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:7]** 
- Silexion is advancing **SIL204**, a second-generation pan-KRAS mutation silencing siRNA, with a **Phase 2/3 clinical trial** planned for **Q2 2026**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:7]** 
- **GMP-grade SIL204** is anticipated to be ready for the Phase 2/3 clinical trial by **Q1 2026**, supported by **strong intellectual property protection** extending until at least **2043**.  **[2022416_0001178913-25-003205_exhibit_99-1.htm:1]** **[2022416_0001178913-25-003205_exhibit_99-1.htm:6]**

Silexion Therapeutics (SLXN)